J.P. Morgan Sticks to Its Buy Rating for Bayer (0P6S)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Bayer today and set a price target of €50.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and Novo Nordisk. According to TipRanks, Vosser has an average return of 1.4% and a 48.21% success rate on recommended stocks.
In addition to J.P. Morgan, Bayer also received a Buy from Barclays’s Charles Pitman CFA in a report issued today. However, on the same day, Jefferies maintained a Hold rating on Bayer (LSE: 0P6S).
The company has a one-year high of €49.78 and a one-year low of €18.38. Currently, Bayer has an average volume of 3.67M.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer: Dose for expansion in PAnTHa study successfully identified
- Bayer reports final results from Phase III PEACE-3 trial of XOFIGO
- Law firms urge judge to delay review of proposed Bayer settlement, Reuters says
- Bayer files false advertising suit against J&J and Janssen Biotech
- 0P6S Earnings Report this Week: Is It a Buy, Ahead of Earnings?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.